- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02664103
Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer (METRO-ABC)
30 de enero de 2018 actualizado por: Sanofi
A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer
Primary Objectives:
- To assess the safety for each cohort of patients on a fixed-dose combination pill of capecitabine and cyclophosphamide administered at flat dose and with metronomic schedule (defined as continuous daily treatment without interruption) in patients with metastatic breast cancer.
- To assess the pharmacokinetics (PKs) and bioavailability of the fixed-dose combination pill of capecitabine and cyclophosphamide administered at different doses/regimens by metronomic schedule in patients with metastatic breast cancer.
Secondary Objectives:
- To assess antitumor activity of the fixed-dose combination pill of capecitabine and cyclophosphamide administered at different doses/regimens by metronomic schedule in patients with metastatic breast cancer given at 3 different doses and schedules (regimen 1=standard dose twice daily [BID], regimen 2=full dose once daily [OD], regimen 3=low dose [OD])
- Disease Control Rate (DCR)
- Overall Response Rate (ORR)
- Time to Progression (TTP) using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1).
- To evaluate the compliance under treatment.
- To describe evolution of toxicities.
- To assess safety all along patient's treatment.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary objective will be evaluated at 12 weeks.
Patients who show evidence of efficacy will be treated and followed-up until progression of the disease.
Tipo de estudio
Intervencionista
Inscripción (Actual)
2
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Kollkata, India, 700053
- Investigational Site Number 356009
-
Mumbai, India, 400012
- Investigational Site Number 356002
-
New Delhi, India, 110085
- Investigational Site Number 356007
-
Trivandrum, India, 695011
- Investigational Site Number 356008
-
Vellore, India, 632004
- Investigational Site Number 356001
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 65 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion criteria:
- Female ≥18 and ≤65 years old.
- Patients with histologically or cytologically confirmed Metastatic Breast Cancer (HER2 negative, ER/PR positive or negative), who are candidates to receive capecitabine and cyclophosphamide as per Investigator's judgment, and meet either one of the following characteristics:
- Recurrence of the disease following at least 2 lines of chemotherapy failure for metastatic triple negative breast cancer.
- In ER/PR positive breast cancer, recurrence of the disease following at least 1 line of chemotherapy failure and 2 lines of hormonal therapy failure.
- Patients who have been previously treated with capecitabine can be recruited in the study provided:
- As per the Investigator's opinion, patients will benefit from this chemotherapy AND
- For prior single administration of capecitabine: at least 6 months has elapsed between last capecitabine treatment and initiation of study treatment.
- For prior capecitabine-based combination regimen: at least 12 months has elapsed between last capecitabine-based treatment and initiation of study treatment.
- At least one unidimensionally measurable lesion according to RECIST criteria version 1.1.
- An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
- Life expectancy of >3 months.
- Patients who are willing to undergo (oral) chemotherapy for the treatment of their disease and who are expected to comply with the treatment and study procedures, as per the Investigator's judgment.
- For women of child bearing potential, documented negative pregnancy test and agreement to use acceptable birth control measures during the duration of the study.
- Signed Informed consent obtained prior to any study related procedures.
Exclusion criteria:
- Patients who are HER 2 positive.
- Patients with 3 or more lines of chemotherapy failure for metastatic triple negative breast cancer.
- In ER/PR positive breast cancer, recurrence of the disease following 2 or more lines of chemotherapy failure and/or 3 or more lines of hormonal therapy failure.
- Patients presenting with de novo stage IV metastatic breast cancer, not previously treated for their disease.
- Patients who have already received any metronomic chemotherapy regimen.
- Known hypersensitivity to capecitabine or to any of its components.
- Known hypersensitivity to 5-fluorouracil.
- Known hypersensitivity to cyclophosphamide or any of its components.
- History of bladder carcinoma.
- Systemic anticancer therapy (chemotherapy, hormone therapy, or radiotherapy) within 4 weeks of randomization for the study.
- History of unexplained hematuria.
- History of dihydropyrimidine dehydrogenase (DPD) deficiency.
- Severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault]).
- Concomitant warfarin treatment.
- History of significant cardiac disease (eg, unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) within the previous 6 months.
- Conditions/situations such as:
- Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, Study coordinator, other staff, or relative thereof, directly involved in the conduct of the protocol.
- Uncooperative Patient or any condition that could make the Patient potentially noncompliant to the study procedures.
- Pregnant or breast-feeding women.
- Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy.
- Patients with a possibility of active tuberculosis as suggested by:
- Any signs or symptoms suggestive of active tuberculosis upon medical history or clinical examination.
- Chest radiograph within 3 months prior to the screening visit consistent with tuberculosis infection.
- Patients with close contact with a person with active tuberculosis.
- Known history of Human Immunodeficiency Virus (HIV).
- Any other significant medical conditions which in the judgment of the Investigator would preclude completion of the study.
- Participation in a clinical research study evaluating another investigational drug or therapy within 30 days prior to the Screening Visit.
- Presence of any of the following laboratory abnormalities at the Screening Visit:
- Hemoglobin <8.5 g/L;
- White blood cell (WBC) <3000/μL;
- Platelet count <100 000/μL;
- Absolute neutrophil count (ANC) <1500/μL;
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 x upper limit of normal (ULN) (or > 5 x ULN in patients with liver metastasis);
- Total Bilirubin >1.5 X ULN (or > 2 x ULN in patients with liver metastasis).
- Patients with a body surface area (BSA) <1.0 m² or 1.8 m².
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: SAR439281(Cohort 1)
Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
|
Pharmaceutical form:Tablet Route of administration: Oral
|
Experimental: SAR439281(Cohort 2)
Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
|
Pharmaceutical form:Tablet Route of administration: Oral
|
Experimental: SAR439281(Cohort 3)
Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
|
Pharmaceutical form:Tablet Route of administration: Oral
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Proporción de pacientes con eventos adversos
Periodo de tiempo: 12 semanas
|
12 semanas
|
Assessment of PK parameter: maximum concentration (Cmax)
Periodo de tiempo: Daily 12 weeks
|
Daily 12 weeks
|
Assessment of PK parameter: time to reach Cmax (Tmax)
Periodo de tiempo: Daily 12 weeks
|
Daily 12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Disease Control Rate (DCR)
Periodo de tiempo: 12 weeks
|
12 weeks
|
Objective Response Rate (ORR)
Periodo de tiempo: 12 weeks
|
12 weeks
|
Time to Progression (TTP)
Periodo de tiempo: 12 weeks
|
12 weeks
|
Proportion of patients compliant with treatment
Periodo de tiempo: 12 weeks
|
12 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
23 de enero de 2016
Finalización primaria (Actual)
6 de noviembre de 2017
Finalización del estudio (Actual)
6 de noviembre de 2017
Fechas de registro del estudio
Enviado por primera vez
15 de enero de 2016
Primero enviado que cumplió con los criterios de control de calidad
21 de enero de 2016
Publicado por primera vez (Estimar)
26 de enero de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
1 de febrero de 2018
Última actualización enviada que cumplió con los criterios de control de calidad
30 de enero de 2018
Última verificación
1 de enero de 2018
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades de la piel
- Neoplasias
- Neoplasias por sitio
- Enfermedades de los senos
- Neoplasias de mama
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antirreumáticos
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos, alquilantes
- Agentes alquilantes
- Agonistas mieloablativos
- Ciclofosfamida
- Capecitabina
Otros números de identificación del estudio
- CAPCYR07568
- U1111-1166-1149 (Otro identificador: UTN)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama metastásico
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos